Search Results - malathy+(mala)+shanmugam

3 Results Sort By:
A Predictive Marker and Treatment to Sensitize Multiple Myeloma Patients to Venetoclax (ABT-199)
Application A marker that predicts Venetoclax (ABT-199) sensitivity that can also be targeted with a drug to help multiple myeloma patients. Key Benefits Marker that predicts if venetoclax will be an effective treatment in multiple myeloma patients. A drug that targets venetoclax resistant multiple myeloma cells to improve treatment in patients. Market...
Published: 7/30/2024   |   Inventor(s): Malathy (mala) Shanmugam, Richa Bajpai
Keywords(s): Biologic, Biomarker, Oncology, Repurposed Drug, Target
Category(s): TechPub Algolia > Diagnostics
Drug Combination to Treat Lung Cancer Metastasis
Application Combination product co-targeting PDH and GLUT1 to inhibit lung cancer metastasis. Key Benefits Combination of drugs exhibits greater synergism in cancer cell lines (H1299, 4T1, H1792). Has potential to prevent metastasis in a variety of cancers. Decreases both cell viability and invasive area. Repurposed drugs. Market Summary Metastatic...
Published: 7/30/2024   |   Inventor(s): Malathy (mala) Shanmugam, Adam Marcus
Keywords(s): Oncology, Repurposed Drug, Small Molecule
Category(s): TechPub Algolia > Therapeutics
Combination Therapy for Increasing Venetoclax Sensitivity in Multiple Myeloma
Application Marker and co-therapy that inhibits succinate dehydrogenase to increase patient response to venetoclax. Key Benefits Co-therapy increases MM sensitivity to venetoclax treatment. Identifies patients who will respond to venetoclax therapy. Market Summary Multiple Myeloma (MM) is a cancer of plasma cells responsible for making antibody...
Published: 10/28/2024   |   Inventor(s): Malathy (mala) Shanmugam, Richa Bajpai
Keywords(s): Biologic, Biomarker, Oncology, Rare/Orphan Diseases, Repurposed Drug, Target
Category(s): TechPub Algolia > Diagnostics, TechPub Algolia > Therapeutics, TechPub Algolia > Drug Discovery